JASPER THERAPEUTICS INC (JSPR) Stock Analyst Earnings Estimates
NASDAQ:JSPR - Nasdaq - US4718712023 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 28,436.74% | N/A 252.39% | N/A 110.43% | N/A 23.69% | N/A 27.65% | |||||||
| EBITDA YoY % growth | N/A | N/A | -36.456M | -50.221M -37.76% | -67.753M -34.91% | -74.866M -10.50% | N/A -24.70% | N/A -24.68% | N/A -17.67% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.71M | -20.683M -339.13% | -36.833M -78.08% | -51.196M -38.99% | -68.861M -34.50% | -76.239M -10.71% | N/A -20.08% | N/A -18.91% | N/A -18.51% | N/A 12.58% | N/A 81.59% | N/A 1,052.18% | N/A 98.52% | N/A 51.68% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -10.30 55.00% | -6.20 39.81% | -4.86 21.61% | N/A 1.05% | N/A 10.45% | N/A -7.53% | N/A -17.24% | N/A 62.24% | N/A 349.00% | N/A -116.38% | N/A 126.83% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.35 -39.48% | -1.20 3.52% | -1.11 31.35% | -0.86 39.35% | -0.93 31.40% | -0.95 20.71% | -0.98 11.96% |
| Revenue Q2Q % growth | N/A | N/A | N/A | ||||
| EBITDA Q2Q % growth | -23.032M -49.50% | -24.072M -28.31% | -24.5M -2.46% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -22.83M -42.75% | -22.79M -14.58% | -22.433M 11.28% | -26.25M -20.40% | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -1.41 -36.89% | -1.34 | -0.07 | -5.32% |
| Q4 2024 Q2Q % growth | -1.62 -8.00% | -1.25 | -0.37 | -29.09% |
| Q3 2024 Q2Q % growth | -1.24 22.50% | -1.09 | -0.15 | -13.47% |
| Q2 2024 Q2Q % growth | -0.97 35.33% | -1.11 | 0.14 | 12.67% |
| Q1 2024 Q2Q % growth | -1.03 35.63% | -1.25 | 0.22 | 17.57% |
| Q4 2023 Q2Q % growth | -1.50 58.33% | -1.65 | 0.15 | 8.94% |
| Q3 2023 Q2Q % growth | -1.60 50.00% | -1.58 | -0.02 | -1.04% |
| Q2 2023 Q2Q % growth | -1.50 48.28% | -1.53 | 0.03 | 1.83% |
| Q1 2023 Q2Q % growth | -1.60 -166.67% | -1.66 | 0.06 | 3.41% |
| Q4 2022 Q2Q % growth | -3.60 54.43% | -3.67 | 0.07 | 1.96% |
| Q3 2022 Q2Q % growth | -3.20 84.24% | -3.49 | 0.29 | 8.40% |
| Q2 2022 Q2Q % growth | -2.90 | -3.20 | 0.30 | 9.26% |
| Q1 2022 Q2Q % growth | -0.60 | -3.57 | 2.97 | 83.19% |
| Q4 2021 Q2Q % growth | -7.90 | -3.50 | -4.40 | -125.48% |
| Q3 2021 Q2Q % growth | -20.30 | -2.82 | -17.48 | -620.43% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0.85% | 1.39% | 0% | 5.35% |
| Revenue | N/A | N/A | N/A | -100% |